Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment
Fernando Campos1, Bernd Kasper2
1Sarcoma Reference Center, A.C.Camargo Cancer Center (ACCCC), Sao Paulo, Brazil.
Introduction:
Desmoid tumor (DT) is a rare, locally aggressive, mesenchymal neoplasm that can arise at any site in the body. Medical therapies play a major role for DT's patients requiring treatment. A novel systemic approach has recently emerged with Nirogacestat, a γ-secretase inhibitor targeting the NOTCH signaling pathway.
Areas Covered:
Nirogacestat is the first drug in its class to receive approval from the Food and Drug Administration (FDA) and is the first FDA-approved treatment specifically for DTs. We reviewed the data leading to its discovery, including its mechanism of action, pharmacological properties, clinical efficacy, and its positioning within the current treatment armamentarium for DTs.
Expert Opinion:
High-quality evidence for systemic therapies in the management of DTs remains an unmet need. Nirogacestat now joins sorafenib as the only drugs with efficacy in DTs demonstrated by randomized phase 3 studies. Currently, there are no comparative trials of the available systemic therapies. Therefore, physicians should consider factors such as drug accessibility, cost, toxicity profile, comorbidities, and patient preferences when selecting treatment. Long-term efficacy and safety data will be essential for evaluating the duration of treatment response and monitoring late-onset side effects of Nirogacestat.
Insights
Nirogacestat is a new FDA-approved treatment for desmoid tumors (DTs), targeting the NOTCH pathway. It offers a novel systemic therapy option for DT patients, joining sorafenib as a drug with demonstrated efficacy in phase 3 studies.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Desmoid tumors (DTs) are rare, locally aggressive neoplasms requiring effective medical therapies.
- Systemic treatments for DTs have historically lacked high-quality evidence.
- The NOTCH signaling pathway is implicated in DT pathogenesis.
Purpose of the Study:
- To review the discovery and development of Nirogacestat, a novel systemic therapy for DTs.
- To evaluate the clinical efficacy and mechanism of action of Nirogacestat.
- To position Nirogacestat within the current treatment landscape for DTs.
Main Methods:
- Review of preclinical and clinical data supporting Nirogacestat's development.
- Analysis of Nirogacestat's mechanism of action as a gamma-secretase inhibitor.
- Evaluation of Nirogacestat's efficacy and safety data from clinical trials.
Main Results:
- Nirogacestat is the first FDA-approved drug specifically for DTs.
- Nirogacestat demonstrates clinical efficacy in DT management, supported by phase 3 studies.
- Nirogacestat targets the NOTCH signaling pathway, offering a novel therapeutic approach.
Conclusions:
- Nirogacestat represents a significant advancement in DT systemic therapy.
- Physicians must consider various factors when selecting systemic therapy for DTs due to the lack of comparative trials.
- Long-term data on Nirogacestat's efficacy and safety are crucial for optimizing treatment duration and monitoring side effects.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
